Pfizer highlights diverse oncology portfolio and combination approaches at ESMO 2024
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
This two-day program was attended by 40 doctors & paramedical staff
Subscribe To Our Newsletter & Stay Updated